淋巴管新生
心脏纤维化
医学
血管内皮生长因子C
巨噬细胞
移植
纤维化
癌症研究
内科学
免疫学
生物
血管内皮生长因子
血管内皮生长因子A
体外
癌症
血管内皮生长因子受体
转移
生物化学
作者
Cuiping Wang,Yue Yuan,Suiqing Huang,Keke Wang,Yao Xiao,Jiantao Chen,Jiaxing Huang,Zhongkai Wu
标识
DOI:10.1080/13880209.2022.2033798
摘要
Therapeutic lymphangiogenesis is a new treatment for cardiovascular diseases. Our previous study showed M2b macrophages can alleviate myocardial ischaemia/reperfusion injury (MI/RI). However, the relation between M2b macrophages and lymphangiogenesis is not clear.To investigate the effects of M2b macrophages on lymphangiogenesis after MI/RI.Forty male Sprague-Dawley (SD) rats were randomized into Sham operation group (control, n = 8), MI/RI group (n = 16) and M2b macrophage transplantation group (n = 16). M2b macrophages (1 × 106) in 100 μL of normal saline or the same volume of vehicle was injected into the cardiac ischaemic zone. Two weeks later, echocardiography and lymphatic counts were performed, and the extent of myocardial fibrosis and the expression of vascular endothelial growth factor C (VEGFC) and VEGF receptor 3 (VEGFR3) were determined. In vitro, lymphatic endothelial cells (LECs) were cultured with M2b macrophages for 6-24 h, and the proliferation, migration and tube formation of the LECs were assessed.In vivo, M2b macrophage transplantation increased the level of lymphangiogenesis 2.11-fold, reduced 4.42% fibrosis, improved 18.65% left ventricular ejection fraction (LVEF) and upregulated the expressions of VEGFC and VEGFR3. In vitro, M2b macrophage increased the proliferation, migration, tube formation and VEGFC expression of LECs. M2b macrophage supernatant upregulated VEGFR3 expression of LECs.Our study shows that M2b macrophages can promote lymphangiogenesis to reduce myocardial fibrosis and improve heart function, suggesting the possible use of M2b macrophage for myocardial protection therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI